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AbstrACt
Introduction Substantial resources are required to 
provide lifelong postoperative care to people with cochlear 
implants. Most patients visit the clinic annually. We 
introduced a person-centred remote follow-up pathway, 
giving patients telemedicine tools to use at home so they 
would only visit the centre when intervention was required.
Objectives To assess the feasibility of comparing a 
remote care pathway with the standard pathway in adults 
using cochlear implants.
Design Two-arm randomised controlled trial. 
Randomisation used a minimisation approach, controlling 
for potential confounding factors. Participant blinding 
was not possible, but baseline measures occurred before 
allocation.
setting University of Southampton Auditory Implant 
Service: provider of National Health Service care.
Participants 60 adults who had used cochlear implants 
for at least 6 months.
Interventions Control group (n=30) followed usual 
care pathway. Remote care group (n=30) received care 
remotely for 6 months incorporating: home hearing in 
noise test, online support tool and self-adjustment of 
device (only 10 had compatible equipment). 
Main outcome measures Primary: change in patient 
activation; measured using the Patient Activation Measure.  
Secondary: change in hearing and quality of life; qualitative 
feedback from patients and clinicians. 
results One participant in the remote care group dropped 
out. The remote care group showed a greater increase 
in patient activation than the control group. Changes in 
hearing differed between the groups. The remote care 
group improved on the Triple Digit Test hearing test; 
the control group perceived their hearing was worse 
on the Speech, Spatial and Qualities of Hearing Scale 
questionnaire. Quality of life remained unchanged in both 
groups. Patients and clinicians were generally positive 
about remote care tools and wanted to continue.
Conclusions Adults with cochlear implants were willing 
to be randomised and complied with the protocol. 
Personalised remote care for long-term follow-up is 
feasible and acceptable, leading to more empowered 
patients.
trial registration number ISRCTN14644286.
IntrODuCtIOn
Cochlear implants provide hearing to people 
mainly with severe to profound deafness. 
Around 14 000 people in the UK use cochlear 
implants, increasing by approximately 1200 
new patients each year.1 There are 18 cochlear 
implant centres in the UK, providing surgery, 
an acute phase of adjustment and rehabilita-
tion, and then clinic-led long-term follow-up 
services. Accessing services can involve consid-
erable time commitment, travel expense, 
missed work and family disruption. Most 
clinics provide regular annual follow-up, 
whether or not further intervention is 
needed. This may result in resources being 
used to provide appointments that provide 
little if any benefit to the patient. However, 
routine appointments do provide opportuni-
ties for the clinician to detect deterioration 
in a patient’s hearing or speech recognition. 
Deterioration usually occurs gradually, and 
without tools to test at home, the patient may 
not notice a change and may spend several 
months listening with poorer hearing. The 
following tasks are usually completed in 
routine follow-up appointments: hearing and 
speech recognition testing, device adjust-
ment, rehabilitation, equipment check and 
troubleshooting, and provision of replace-
ment or upgraded equipment. We designed, 
implemented and evaluated remote care 
tools that the patient could use at home to 
manage these tasks. If effective, these tools 
could mean that people using cochlear 
strengths and limitations of this study
 ► This is the first randomised controlled trial of a triple 
approach to remote care for adults using cochlear 
implants.
 ► Six months of follow-up may be insufficient to high-
light benefits and limitations of remote care.
 ► People who volunteered to take part in a trial of re-
mote care may not be representative of the broader 
population of people with cochlear implants.
 ► The Patient Activation Measure may not be very sen-
sitive to changes in empowerment in people using 
cochlear implants due to its medical perspective.
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implants could only attend the clinic when intervention 
is required, eliminating the need for routine clinic-led 
appointments.
Potential benefits for the patient from the use of these 
remote care tools are:
 ► increased confidence to manage one’s own hearing;
 ► more stable hearing as problems could be identified 
and resolved quicker;
 ► more appropriate adjustments of the cochlear implant 
processor in real-life situations as they provide an 
ability to fine-tune when away from clinic;
 ► convenience of not travelling to routine appointments;
 ► reduction of travel cost and time, time off work and 
disruption to family life;
 ► greater equality in service delivery as routine support 
can be accessed regardless of distance from clinic.
Patients who are empowered and involved in their 
care tend to have better outcomes,2 3 and those using 
self-management tools show a significant improvement in 
outcomes.4 Clinics may be able to improve use of resources 
through reducing the need for follow-up appointments.
MethODs
trial design and setting
This was a 6-month two-arm randomised controlled 
trial (RCT) involving 60 adults with at least 6 months 
of cochlear implant experience; the protocol was previ-
ously published.5 The trial was conducted at the Univer-
sity of Southampton Auditory Implant Service (USAIS), 
a tertiary treatment centre mostly funded by National 
Health Service referrals. We followed the Consolidated 
Standards of Reporting Trials (CONSORT) guidelines 
for RCTs.
recruitment
The project was advertised on the USAIS website (www. 
ais. southampton. ac. uk), a link was tweeted from @UoS_
AIS and @CIRemoteCare. The study was also publicised 
by the National Cochlear Implant Users Association. The 
primary investigator (PI) accessed the USAIS clinical data-
base and contacted all patients who fulfilled the inclusion 
criteria, except those who had indicated that they did not 
want to receive research invitations. Sample sizes between 
30 and 50 are suggested for a feasibility trial.6 7 We chose 
60 to allow a range of different patients and to account 
for attrition.
Inclusion criteria
 ► person using one or two cochlear implants (any 
make(s)/model(s)) for at least 6 months;
 ► living in the UK;
 ► aged 18 years or more;
 ► able to give informed consent;
 ► sufficient English to understand study documentation 
and participate in testing;
 ► access to a computer or device with internet access.
Exclusion criteria
 ► Those who did not fulfil the inclusion criteria plus any 
medical condition or known disability that would limit 
their capacity to use the remote care tools.
staff change management assessment
Moving to remote care represents a significant change 
to staff at cochlear implant centres. The protocol indi-
cated that formal staff interviews would be conducted at 
3-month intervals over the 6-month follow-up period; that 
is, at baseline, 3 months and 6 months. However, early 
interviews suggested that most staff did not feel affected 
by the introduction of remote care as only 30 out of the 
total case load of well over 1000 patients were on a remote 
pathway. A formal staff change management assessment 
was therefore not conducted and a smaller number of 
interviews with audiologists, rehabilitationists and clinical 
support staff were carried out to capture qualitative staff 
feedback.
Interventions
Control group: standard clinical care pathway
Participants in the control group continued with their 
usual clinic-based care pathway, without access to the 
remote care tools. This involved either clinic-led or 
patient-instigated appointments at the centre for device 
programming, monitoring outcomes, rehabilitation 
support or equipment maintenance.8 Appointments are 
frequent in the first year and less often subsequently. 
They attended two trial-related visits: one at baseline and 
another at exit.
Intervention group: remote care
Those randomised into the treatment group (remote 
care group) received cochlear implant care remotely for 
6 months. Participants were told that clinic appointments 
would still be arranged if requested by the patient or if a 
clinician deemed it necessary. They were also informed 
that they needed to adhere to any medical check-ups 
with the cochlear implant surgeon. However, no routine 
follow-up appointments were scheduled for the trial dura-
tion. Participants were able to access the remote care tools 
as often as they wished, but had protocol requirements in 
order to assess compliance. Remote care comprised:
Remote and self-monitoring
Participants in the remote care arm accessed a pass-
word-protected online hearing in noise test based on 
the Triple Digit Test (TDT); each participant had an 
individual log-in. The customised site was provided by 
the charity Action on Hearing Loss. Each time a partic-
ipant completed the test, the results were emailed to 
the research team and included a code to identify the 
participant. Participants listened to sets of three digits 
in background noise and typed in the numbers they 
heard. If they entered all three digits correctly, the noise 
level increased. An incorrect response caused a decrease 
in noise. Full methodological details of the test have 
been published elsewhere.9 Participants were advised 
 o
n
 23 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019640 on 20 April 2018. Downloaded from 
3Cullington H, et al. BMJ Open 2018;8:e019640. doi:10.1136/bmjopen-2017-019640
Open Access
that although a direct connection between the sound 
processor and the computer eliminates the effects of back-
ground noise, testing with the computer speakers allows 
assessment of the whole hearing pathway including the 
microphone—a part that commonly deteriorates due to 
dust, humidity or damage. The protocol required partic-
ipants to complete the hearing test a minimum of two 
times: month 1 and month 6 of the trial. However, partic-
ipants could complete the test at any other time during 
the 6 months. Participants were encouraged to experi-
ment with different processor settings and programs and 
redo the test whenever they wanted. They were advised 
to keep the test parameters the same, as change in result 
(rather than the absolute value) was the variable of 
interest. Those participants using a Cochlear CP810 or 
CP910 sound processor (n=12) were also loaned an iPad 
with a calibrated TDT installed.
Self-adjustment of device (Remote Assistant Fitting)
Only those people using newer cochlear implant devices 
manufactured by Cochlear (CI500 series, CI422 or 
CI24RE implants using CP800 or CP900 series proces-
sors) were able to participate in the trial of device self-ad-
justment. The other manufacturers of cochlear implant 
systems did not have equivalent tools available at the time 
of the trial. Remote Assistant Fitting allows adjustment of 
bass, treble and master volume in addition to the usual 
sensitivity and volume settings.10 All participants with 
compatible processors were given brief group instruction 
on the use of Remote Assistant Fitting at the baseline 
visit. A reset facility allowed participants to return their 
device to the original settings established at the clinic. 
The protocol required participants to perform a self-ad-
justment at least twice (in months 1 and 6), but additional 
adjustments could be done at any time. It was not possible 
to receive logs of the changes made, so this was measured 
by self-report using a written question to ascertain usage 
at study exit.
Online support tool
The research team designed a new online support tool 
for adults with cochlear implants using LifeGuide.11 Life-
Guide is an open-source software platform that allows 
the development and trialling of interactive, tailored 
web-based interventions. This was a codesign process 
incorporating feedback from service users at all stages, 
including focus groups. The online support tool (Cochlear 
Implant Remote Care, CIRCA) contained personalised 
equipment help and information, troubleshooting, reha-
bilitation, goal-setting, help with music and telephone 
use and a method of ordering replacement equipment. 
The site was designed to be accessible to people who 
may be inexperienced internet users; training occurred 
at the baseline visit. It also stored the TDT hearing in 
noise test result entered by the participant and provided 
appropriate feedback (‘no significant change’ or ‘signifi-
cantly worse: contact the centre’). Participants were 
given a unique user name to log in to this tool and they 
could access it at any time; the protocol only required site 
registration so they could choose how often they used it. 
They had the option to include a mobile phone number 
to receive reminder text messages for speech processor 
maintenance and study information. The site also 
collected usage and flow data from participants’ interac-
tions with the system, and welcomed comments about the 
site. These data are informing design of the next version.
In the UK, speech processors are generally upgraded 
every 5 years.8 Those patients in the trial who were eligible 
for a processor upgrade received the new equipment at 
home rather than coming into the clinic. Clinicians set 
up the required maps; these were downloaded onto the 
processors by the cochlear implant company who sent the 
equipment directly to the patient.
Outcome measures
The following outcomes were measured at baseline and at 
study exit (ie, at 6 months):
 ► patient activation measured using Patient Activation 
Measure (PAM);
 ► speech recognition assessed using Bamford-Kowal-
Bench (BKB) sentences in quiet and noise, and also 
assessed using the TDT;
 ► listening ability measured using the Speech, Spatial 
and Qualities of Hearing Scale (SSQ) questionnaire;
 ► health-related quality of life measured using the 
Health Utilities Index (HUI) Mark 3.
The PAM is a well-validated generic measure of patient 
activation that evaluates the knowledge, skills, beliefs and 
behaviours that patients have for self-management of their 
long-term condition.12 13 It is a one-page questionnaire 
comprising 13 statements about health. The subjects are 
asked to indicate how much they agree or disagree with 
each statement on a 4-point Likert-type scale.12
BKB sentences14 are the standard clinical speech recog-
nition test used in the UK. Testing was conducted in quiet 
and in background noise. Full details of the test method 
are published elsewhere.15 For the test in quiet, the 
outcome measure was the percentage of keywords iden-
tified correctly. If a participant repeated 70% or more 
keywords correctly, an adaptive presentation of noise was 
also included. The dependent variable was the speech 
reception threshold (SRT) in dB. A lower score indicates 
that the listener can cope with a more challenging signal-
to-noise ratio.
The TDT was conducted in clinic at baseline and at 
exit using the same Action on Hearing Loss online test 
that participants in the remote care arm used at home. 
The dependent variable was the SRT in dB. Testing was 
done using an Anker mini speaker (A7910) to present the 
stimuli at a comfortable level; those using two (bilateral) 
implants were tested with both together. These two speech 
recognition tests were chosen because BKB sentences are 
used clinically in the UK, and the TDT was the test used 
at home in the project.
The SSQ is a 49-item questionnaire measuring self-re-
ported hearing disability over three domains: difficulties 
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understanding speech in different situations, localising 
and tracking sounds, and ease of listening and natural-
ness of sound.16 The HUI Mark 3 (HUI3) is a multiat-
tribute health status classification system evaluating eight 
domains of vision, hearing, speech, ambulation, dexterity, 
emotion, cognition and pain.17 Participants’ responses 
were used to derive ‘utility values’ for their health states 
based on the preferences of a sample of the Canadian 
public.18
Demographic data were collected including highest 
formal educational qualification based on categories used 
in the Office for National Statistics 2011 census. Initially, 
a log of clinic contacts was kept in order to evaluate the 
workload in the two groups. However, it became diffi-
cult to separate study-related contact from clinical care 
contact.
Participants in the remote care group attended a focus 
group at study exit to explore and clarify views on remote 
care using structured questions.
Primary outcome measure
 ► Change (from day of study entry to 6 months follow-up) 
in patient activation measured using the PAM.
Secondary outcome measures
 ► stability of hearing measured by change (from day of 
study entry to 6 months of follow-up) in speech recog-
nition measured in clinic using BKB sentences, the 
TDT and the SSQ;
 ► stability of quality of life measured by change (from 
day of study entry to 6 months of follow-up) in quality 
of life measured using the HUI3;
 ► patient preference for and experience of remote care 
in treatment arm reported qualitatively from feedback 
in online support tool and focus groups at study exit;
Table 1 Demographics of 60 trial participants
Measure 
Control 
group (n=30)
Remote care 
group (n=30)
Age (years) 
  Mean 63 64
  SD 12 14
  Median 68 69
  Range 35–80 20–83
Gender 
  Female 17 19
  Male 13 11
Distance from home to clinic (miles) 
  Mean 39 46
  SD 25 36
  Median 34 39
  Range 9–106 5–156
Cochlear implant manufacturer 
  Advanced Bionics (AB) 9 4
  Cochlear 14 12
  Cochlear in one ear, AB in the 
other ear
1 0
  MED-EL 4 13
  Neurelec/Oticon  
Medical
2 1
Speech processor 
  AB Harmony 1 1
  AB Naida 9 4
  Cochlear CP810 3 9
  Cochlear CP910 10 4
  Cochlear Freedom 2 1
  MED-EL Opus 2 4 9
  MED-EL Rondo 1 2
  MED-EL Sonnet 0 2
  Neurelec/Oticon Medical 
Saphyr
2 1
Unilateral or bilateral implant 
  Unilateral 28 27
  Bilateral 2 3
Qualification 
  No qualifications 1 3
  Level 1 (1–4 GCSEs, Scottish 
Standard Grade or equivalent 
qualifications)
3 1
  Level 2 (5 or more GCSEs, 
Scottish Higher, Scottish 
Advanced Higher or equivalent 
qualifications)
4 3
  Apprenticeship 0 2
  Level 3 (2 or more A-levels, 
HNC, HND, SVQ level 4 or 
equivalent qualifications)
6 2
Continued
Measure 
Control 
group (n=30)
Remote care 
group (n=30)
  Level 4+ (first or higher 
degree, professional 
qualifications or other 
equivalent higher education 
qualifications)
15 18
  Other qualifications 1 0
Cochlear implant clinic 
  Birmingham 1 0
  Cambridge 1 1
  Oxford 3 0
  Royal National Throat Nose 
and Ear, London
1 2
  Southampton 24 27
GCSE, General Certificate of Secondary Education; HNC, 
Higher National Certificate; HND, Higher National Diploma; 
SVQ, Scottish Vocational Qualification.
Table 1 Continued 
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 ► clinician preference for and experience of remote 
care measured qualitatively from interviews with staff.
Feasibility outcomes
 ► recruitment (number of eligible and willing 
participants)
 ► attrition (dropout) and bias
 ► adherence to protocol
 ► acceptability of randomisation to service users
 ► willingness to use and ability to access remote care 
tools (compliance with minimum use).
hypotheses
Primary
The remote care group will show a greater increase in 
patient activation over the 6-month remote care trial 
period than the control group, measured using the PAM.
Secondary
1. There will be no more deterioration in hearing in the 
remote care group compared with the control group, 
measured using speech recognition (BKB, TDT) and 
the SSQ questionnaire.
2. There will be no more deterioration in quality of life 
in the remote care group compared with the control 
group, measured using the HUI3.
3. Service users (patients) will feel positive about remote 
care, measured qualitatively from feedback in online 
support tool and in focus groups.
4. Clinicians will feel positive about remote care, mea-
sured qualitatively from interviews with clinical staff.
randomisation
Participants were allocated to groups at the baseline 
visit after consenting to participate and after baseline 
measures had been obtained. Allocation to the remote 
care pathway or to the standard care pathway was done by 
the PI (HC) using minimisation software.19 Minimisation 
seeks to achieve a balance across the arms of a trial on 
one or more predefined patient characteristics.20 21 The 
minimisation balanced the following factors:
 ► cochlear implant user less than a year or more than 
a year
 ► gender
 ► distance from the clinic (local or non-local, defined 
as within 20 miles or more than 20 miles away, 
respectively)
 ► device (Cochlear or not)
 ► use of equipment compatible with Cochlear Remote 
Assistant Fitting (or not).
Gender was included because men are more likely to 
use the internet than women, especially in the older age 
group.22 Biased coin minimisation was used with a base 
probability of 0.7. Group imbalance was quantified using 
the marginal balance method.23
blinding
Due to the nature of the intervention, participant blinding 
was not possible. Baseline measures were therefore 
obtained before allocation. When exit measures were 
obtained, clinicians did not know which group the patient 
had been in, although it is possible that the patient could 
have volunteered this information.
statistical analysis
IBM SPSS Statistics V.22 was used. One-tailed p values were 
used in each case that the hypothesis was directional. We 
tested data for normality using the Shapiro-Wilk test and 
used non-parametric statistics when assumptions were 
violated.
Data handling
Data were managed according to the University of South-
ampton Research Data Management Policy.
results
Demographics
Figure 1 shows the CONSORT flow chart for the trial. 
Table 1 shows the demographic characteristics of the 
participants in each group.
evaluation outcomes
Baselines measures occurred from 9 to 29 January 2016; 
exit measures occurred from 11 July to 10 August 2016. 
One subject (in the remote care group) withdrew from 
the project because she was having problems with the 
computer and decided she preferred face-to-face interac-
tions with a clinician and therefore no exit measures were 
obtained. Two further subjects in the remote care group 
were too ill to attend the exit appointment so did not 
complete the clinic-based hearing tests, but completed 
exit questionnaires at home.
Primary outcome measure: change in patient activation
Figure 1 shows the number available for analysis in each 
group. Ten out of 13 questions need to be answered 
in order to obtain a valid overall score; answering ‘Not 
applicable’ to more than three questions would make 
the questionnaire invalid. The PAM was scored using a 
spreadsheet supplied by Insignia which sums and norma-
lises the items to a 100-point scale, with a higher score 
reflecting a greater level of activation.
PAM scores were normally distributed in both groups at 
baseline and exit. The baseline PAM score was not related 
to age (Pearson correlation r=−0.068, p=0.615, n=57) 
but those participants with a higher level of qualifica-
tion tended to have a higher baseline PAM score (Jonck-
heere-Terpstra test=3.126, p=0.002, n=57).
As hypothesised, patient activation increased more in 
the remote care arm (mean PAM change score=2.38, 
SD=10.16) compared with the usual care arm (mean 
PAM change score=−3.44, SD=14.59) (one-way analysis 
of variance (ANOVA) F(1,52)=2.89, one-tailed p=0.048) 
(figure 2). The effect size was medium (Cohen’s d=0.5). 
The primary hypothesis was retained: the remote care 
group showed a greater increase in patient activation 
than the control group.
 o
n
 23 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019640 on 20 April 2018. Downloaded from 
6 Cullington H, et al. BMJ Open 2018;8:e019640. doi:10.1136/bmjopen-2017-019640
Open Access 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart of project participants. BKB, Bamford-Kowal-
Bench; HUI3, HUI Mark 3; PAM, Patient Activation Measure; SSQ, Speech, Spatial and Qualities of Hearing Scale; TDT, Triple 
Digit Test. 
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Secondary outcome measures
Stability of hearing
BKB sentences
The CONSORT flow chart shows number of participants. 
The dependent variable was change in score. For BKB 
sentence testing in quiet and adaptive noise, the remote 
care group did not deteriorate more than the control 
group (quiet: Mann-Whitney U test, one-tailed p=0.475; 
adaptive noise: Mann-Whitney U test, one-tailed p=0.266).
Triple Digit Test
Figure 1 shows the number of participants included. In 
its current iteration, the test was too difficult for some 
people—they were only able to identify the correct 
set of three digits a few times or not at all, even at the 
most favourable signal-to-noise ratio. In line with the 
procedure recommended by Wetherill and Levitt,24 
those stimulus runs exhibiting less than six reversals 
on the adaptive staircase were excluded from analysis. 
The number of reversals for each test was calculated by 
analysing the follow-up email sent automatically to the 
researcher after each test. This email was not sent in 13 
tests at baseline and four at exit, although the final SRT 
was noted on paper by the clinician at the time. It is 
unclear whether this was a website error or clinician user 
error. In those cases where the number of reversals was 
not known, the SRT result was not included. The change 
in TDT SRT was calculated by subtracting the exit SRT 
from the baseline SRT. This produced a positive result 
if the participant scored better at the exit of the study 
than at the baseline because a lower score is better on 
the SRT measure.
Only 14 participants in each group were known to 
have obtained six or more reversals at both the base-
line and exit measure. Contrary to our expectations, 
the control group deteriorated significantly more than 
the remote care group (one-way ANOVA F(1,26)=8.641, 
one-tailed p=0.004). While the remote care group 
showed an improvement in the TDT after the project 
(mean change=2.32 dB, SD=3.38 dB), the control group 
showed a slight deterioration (mean change=−1.29 dB, 
SD=3.12 dB). The effect size was large (Cohen’s d=1). 
Figure 3 shows the change in TDT SRT in the control and 
remote care groups. The secondary hypothesis related to 
hearing deterioration as measured with the TDT is there-
fore rejected.
SSQ questionnaire
The SSQ was analysed by obtaining an overall average 
score. Thirty-nine out of 49 questions were required to 
be answered in order to obtain a score; resulting in the 
exclusion of one baseline result and two exit results. One 
participant was excluded from the comparison because 
they had made an assumption that they should answer the 
questionnaires thinking about their ability to hear without 
lip-reading at the exit point but not at the baseline.
Figure 2 Change in Patient Activation Measure (PAM) score from baseline to study exit in control (n=27) and remote care 
(n=27) groups. Outliers (more than 1.5 box lengths above or below the box) are shown as circles. The numbers by the markers 
represent individual case identifiers.
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Change in hearing was measured by subtracting the 
baseline overall SSQ score from the overall exit score. The 
mean change in SSQ was −0.35 in the control group and 
0.17 in the remote care group. There was more deterio-
ration in perceived hearing in the control group than in 
the remote care group (one-way ANOVA F(1,52)=6.391, 
one-tailed p=0.008).
Overall the secondary hypothesis 1 that there will be 
no more deterioration in hearing in the remote care 
group compared with the control group was retained. 
The control group deteriorated more than the remote 
care group in the TDT hearing test and in the SSQ 
questionnaire.
Stability of quality of life
Change in the HUI3 utility value was calculated by 
subtracting the baseline measure from the exit measure. 
There was no significant difference in the quality of 
life change between the two groups (one-way ANOVA 
F(1,56)=0.304, one-tailed p=0.292). Secondary hypothesis 
2 was therefore retained as there was no more deteriora-
tion in quality of life in the remote care group compared 
with the control group, measured using the HUI3.
Patient preference for and experience of remote care
This was reported qualitatively from feedback by users 
of remote care in focus groups. The home hearing test 
was reported to be the best feature. Although there were 
only 30 people using the remote care tools, in a 6-month 
period results from 554 home hearing tests were received. 
It is likely that many more tests were done as participants 
told us that they did a lot more tests than they submitted 
through the online support tool. The number of home 
hearing tests logged per participant ranged from 0 to 121, 
with a median of 9 (mean=18, SD=27).
Clinician preference for and experience of remote care
Generally, staff felt positive about remote care and 
patients being given choice, and felt that more tools for 
patients to use at home represented an improvement over 
the current standard care pathway. The main concern 
raised was that the remote care pathway would not be 
suitable for all patients, and that a more extensive roll-out 
should be on an opt-in basis. Some staff felt that a move 
to remote care would have implications for their clinical 
role, in that they would see a higher proportion of more 
complex patients in clinic, which would have a greater 
emotional load for them and may provide a skewed view 
of how well people can hear with a cochlear implant.
Feasibility outcomes
Recruitment (number of eligible and willing participants)
No difficulties were experienced in recruiting 60 partic-
ipants. Many more people with implants had contacted 
the PI to say they were interested in taking part than the 
required sample size.
Figure 3 Change in Triple Digit Test (TDT) speech reception threshold (SRT; dB) from baseline to exit for control (n=14) and 
remote care (n=14) groups.
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Adherence to protocol
Participants in the remote care group were asked to 
access the three remote care tools a minimum number 
of times as follows, but were given no other guidance or 
requirements.
1. Remote and self-monitoring: minimum of two home 
hearing tests—one in the first and one in the last 
month. Twenty-eight out of 30 people (93%) com-
plied. One person did only one home hearing test; 
one person withdrew from the study before they had 
done a home hearing test. Twenty-six out of 30 (87%) 
did a home hearing test in the first month; 24 out of 
30 (80%) did a test in the last month.
2. Self-adjustment of device: do self-adjustment at least 
twice. From self-report, seven out of nine people 
(78%) used self-adjustment at some point. Although 
one of these did not show evidence of use on their 
sound processor, so may have been mistaken. One 
person did not answer the question. Compliance may 
have been six out of nine (67%).
3. Online support tool: register with the site and use it as 
they wished. One hundred per cent compliance.
Acceptability of randomisation to service users
All participants agreed to proceed once the randomi-
sation was explained to them. Some people were disap-
pointed to be in the control group. An information sheet 
was provided to them explaining why the control group 
was important.
Willingness and ability to use remote care tools
All 30 remote care participants signed up for the online 
support tool at the start of the project, although some 
reported initial log-in problems. The number of separate 
log-ins per participant ranged from 1 to 98 with a median 
of 12 (mean=18, SD=22). The total number of log-ins 
during the 6-month trial period was 537.
All participants in the remote care arm were asked to 
answer some questions about the online support tool. 
Responses were received from 27 out of 30 participants. 
One person dropped out, and two people fell ill during 
the trial. Sixty-seven per cent of people found the CIRCA 
website useful, and 64% of people would recommend it 
to other people with cochlear implants. We also received 
a lot of constructive feedback about what people would 
want in the next version.
Ten people were shown how to change their speech 
processor programs using Remote Assistant Fitting. 
Remote Assistant Fitting can only be used with one 
specific device; all eligible participants in the remote care 
arm were provided with the means to use it. Nine of the 
10 eligible participants answered a question at study exit 
about how much they had used Remote Assistant Fitting. 
As expected for such a new tool, feedback was vari-
able. Almost half of the respondents (44%) (n=4) used 
Remote Assistant Fitting ‘all the time’ or ‘often’; 22% 
(n=2) ‘never used it’. One-third (n=3) used it ‘once or 
twice’. One person reported that they had used Remote 
Assistant Fitting ‘all the time’, however it seemed from 
the speech processor settings that it had not been used 
so possibly this participant misunderstood what they were 
being asked.
Five participants in the remote care arm were due 
to receive an upgraded speech processor during the 
study period. These were all users of Cochlear devices. 
One participant had a clinic visit scheduled as she was 
experiencing some hearing problems, so received the 
upgraded equipment on that day. The other four partic-
ipants received their new speech processors at home 
preprogrammed with their settings. They were sent 
an introductory email before receiving the processor, 
with links to videos to get used to their equipment, 
unpacking instructions and details of which programs 
were in the speech processor. Two out of four were 
happy with their upgrades and did not attend clinic 
further. One participant wanted some changes made to 
the programs, which was done by post without seeing 
the patient. One participant attended clinic after the 
clinical trial as he felt he was not hearing so well with 
the new processor.
Adverse events
Six adverse events were logged during the clinical trial. 
Four were unrelated to the treatment (two adverse events 
related to breach of confidentiality, two hospitalisations). 
Two adverse reactions were related to the treatment. One 
participant suffered a headache and nausea after the 
long day of baseline measures. During exit measures, one 
participant and their spouse became upset. Both adverse 
reactions were considered mild and were resolved. Appro-
priate action was taken in all cases in terms of reporting to 
the sponsor and Research Ethics Committee.
DIsCussIOn
This is the first RCT of a triple approach to remote care 
for adults using cochlear implants. The remote care group 
showed a greater increase in patient activation than the 
control group after the 6-month clinical trial. The remote 
care group improved on the TDT hearing test; the control 
group perceived their hearing was worse on the SSQ ques-
tionnaire. Quality of life was unchanged in both groups. 
Patients and clinicians were generally positive about remote 
care tools and wanted to continue. Therefore, the provision 
of remote care is feasible and acceptable in adults using 
cochlear implants, and an RCT is possible.
We used the data on the PAM change score to derive 
an estimate of effect size. The observed effect size (differ-
ence in size of change in PAM between the two groups) 
was 0.463 SD. To detect an effect of that size with power 
of 80%, alpha of 0.05 and 1:1 allocation treatment to 
control would require 59 patients in each group. We 
would recommend a subsequent fully powered RCT has 
this number of participants.
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limitations
Participants who volunteered to take part in a trial of 
remote care are unlikely to be representative of the UK 
population of people using cochlear implants—in terms 
of activation, interest in telemedicine and access to and 
familiarity with technology. Entrants into the study were 
self-selecting. In addition, this study’s participants gener-
ally had a higher level of educational qualification than 
the UK population.
Although not statistically significant, there appeared to 
be a trend towards the control group being less empow-
ered at the end of the follow-up period that the current 
sample size may have been too small to detect. If present, 
such a change may have related to some participants 
feeling disgruntled or disempowered because they were 
allocated to the control group. While patients were 
blinded to their allocation at baseline, they knew whether 
they were in the control or remote care group once allo-
cated. This may have introduced bias.
Out of 118 completed PAM questionnaires (60 at base-
line and 56 at exit), four were not valid due to ‘N/A’ 
being answered for more than three questions. On exam-
ining these responses, the question that was answered 
‘N/A’ the most (27 out of 118 times) was question 4, 
‘I know what each of my prescribed medications do.’ 
The questions with the second and third most ‘N/A’ 
responses were question 9, ‘I know what treatments are 
available for my health problems’ (n=17) and question 8, 
‘I understand my health problems and what causes them’ 
(n=12). Aside from these three questions, the response 
‘N/A’ was provided just zero to three times per question. 
It is apparent that people using cochlear implants are 
different from patients receiving a medical treatment for 
a health condition. They are simply using a technological 
solution to deafness, and may have no health problems 
and take no medication, and do not view their hearing 
loss as related to ill health. The PAM questionnaire and 
other similar scales, for example, the revised Partners in 
Health Scale,25 may therefore provide an overmedicalised 
model of activation in people using cochlear implants and 
may not be the most valid measure of empowerment. A 
measure of beliefs, skills and knowledge specific to users 
of a hearing device may be even more sensitive to changes 
in activation related to the use of remote care tools and is 
under development by the authors.26
The remote care group improved slightly on the TDT 
although their BKB sentence test scores were unchanged. 
During the trial, remote care participants used the TDT 
at home so their improvement may have been a result of 
familiarity and/or a training effect. An alternative expla-
nation could be that the TDT may be more sensitive to 
subtle hearing change than the traditional BKB clinic 
test. The control group on average reported their hearing 
to be worse, although this was not backed up by objective 
data. This may also be related to the fact that the control 
group were not blinded to their allocation at exit, and 
may have felt that they were ‘missing out’ by not having 
access to the remote care tools. The TDT is not suitable 
for wider roll-out in its current form as it was too difficult 
for some people to complete and there were problems 
with receipt of results.
COnClusIOns
Adults with cochlear implants were willing to be 
randomised and comply with the study protocol. Person-
alised remote care for long-term follow-up appears to be 
feasible and acceptable to both patients and clinicians, 
leading to more empowered patients. We are not recom-
mending that all adults with cochlear implants should 
follow a telemedicine pathway; instead we suggest person-
alised stratification of care. This should involve a careful 
process of shared decision-making with the decision about 
which pathway to follow being jointly made between the 
patient, their families and the clinician.27
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